SkinDermic® is a drug discovery company focused on developing breakthrough and innovative small molecule drugs for the treatment of infectious and inflammatory skin diseases. SkinDermic® recently completed proof of concept clinical phase in humans with its First-in-Class treatments for acne and HHV8 associated diseases (Kaposi Sarcoma and Lymphomas). Skindermic owns now a pipeline with very active and very well tolerated new drugs for HHV8 associated diseases and acne vulgaris.